Prostate-specific antigen density: A new prognostic indicator for prostate cancer

Zentner, P.G.; Pao, Lincoln K.; Benson, Mitchell C.; McMahon, Donald J.; Schiff, Peter B.

doi:10.1016/0360-3016(93)90420-z

Cited by 31 publications

(7 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sensitivity rose to 93% if patients in stage A were ex cluded. The levels of PSAD (mean 0.78) ob served in this series were greater than those reported by Benson et al [ 10,11] or Brawer et al [12] who indicated means lower than 0.3, although our results are very similar to those recently published by Zentner et al [14] (mean 0.66) or Bare et al [13] (0.63). These differences may be due to a different assort ment of tumor stages in the series studied.…”

Section: Discussioncontrasting

confidence: 57%

Usefulness of Prostate-Specific Antigen Density as a Diagnostic Test of Prostate Cancer

Filella

Alcover²,

Molina³

et al. 1996

Tumor Biol

View full text Add to dashboard Cite

To evaluate the diagnostic usefulness of prostate-specific antigen density (PSAD) in prostate cancer (PC) prostate-specific antigen (PSA) concentrations were measured in 175 patients with benign prostatic hypertrophy (BPH) and 50 patients with PC. Patients with BPH were classified according to the presence of complications of the disease: urinary infection or the presence of a bladder catheter. PSAD levels were observed to be greater than 0.15 in 3% of the patients with uncomplicated BPH and in 40% of the patients with complicated BPH. PSA levels were higher than 10 µg/l in 3 and 27% of these patients, respectively. High levels of PSAD were observed in 80% of the patients with cancer. Sixty-four percent of the patients with cancer presented PSA levels greater than 10 µg/l. These results indicate that PSAD is a useful parameter in the differential diagnosis of PC and BPH with the diagnostic efficacy of PSAD being greater than that of the serum determination of PSA.

show abstract

Section: Discussioncontrasting

confidence: 57%

Usefulness of Prostate-Specific Antigen Density as a Diagnostic Test of Prostate Cancer

Filella

Alcover²,

Molina³

et al. 1996

Tumor Biol

View full text Add to dashboard Cite

show abstract

“…337 After RT, residual prostatic epithelial cells may produce PSA under androgenic stimulation, and serum levels of PSA may be detected even in the absence of prostate cancer. 317,331,340 Alcantara reported a 10-year distant metastasis rate of 4% versus 19% in men with a 12-month nPSA of ≤2 ng/mL versus >2 ng/mL, p < 0.0001. 227,331,[339][340][341] The nPSA correlates with pretherapy PSA level, tumor grade, and clinical T category 341,342 but is an independent predictor associated with biochemical or clinical relapse, 311,339,340,343 and with local and metastatic tumor control.…”

Section: Disease Sitesmentioning

confidence: 95%

“…249,250,317 Nonetheless, Crook et al 318 affirmed that local tumor recurrence correlated with pretreatment PSA in patients in whom serial post-RT prostatic biopsies were performed. 249,250,317 Nonetheless, Crook et al 318 affirmed that local tumor recurrence correlated with pretreatment PSA in patients in whom serial post-RT prostatic biopsies were performed.…”

Section: Disease Sitesmentioning

confidence: 99%

“…Zagars et al 249 reported a similar finding in a study population in whom post-RT prostatic biopsies were generally obtained to identify an otherwise unknown source for biochemical relapse. Zentner et al 317 evaluated PSAD (i.e., the PSA value divided by prostatic volume) in patients treated with EBRT. 227,285,291 In an effort to improve the prognostic accuracy of pretherapy serum PSA many investigators have examined derivatives of the serum PSA including PSAD (a correction for benign prostate gland volume) or PSA kinetics (velocity of rise or doubling time).…”

Section: Disease Sitesmentioning

confidence: 99%

See 1 more Smart Citation

Prostate Cancer

Michalski¹,

Pisansky²,

Lawton³

et al. 2016

Clinical Radiation Oncology

View full text Add to dashboard Cite

“…Since the timing and frequency of PSA determinations could a ect comparability of results, the board then recommended that PSA determinations be obtained at 3 or 4 month intervals during the ÿrst 2 years following radiotherapy, and every 6 years thereafter. A number of alternative deÿnitions of biochemical failure based on PSA density, PSA doubling time, and size of ÿtted PSA based on quadratic regressions, have also been proposed [2][3][4][5][6]. The aim of this paper is to seek an improved model for prediction of biochemical failure based on behaviour of longitudinal PSA trajectories.…”

Section: Introductionmentioning

confidence: 99%

Predicting time to prostate cancer recurrence based on joint models for non‐linear longitudinal biomarkers and event time outcomes

Pauler

Finkelstein

2002

Statistics in Medicine

View full text Add to dashboard Cite

Biological markers that are both sensitive and specific for tumour regrowth or metastasis are increasingly becoming available and routinely monitored during the regular follow-up of patients treated for cancer. Obtained by a simple blood test, these markers provide an inexpensive non-invasive means for the early detection of recurrence (or progression). Currently, the longitudinal behaviour of the marker is viewed as an indicator of early disease progression, and is applied by a physician in making clinical decisions. One marker that has been studied for use in both population screening for early disease and for detection of recurrence in prostate cancer patients is PSA. The elevation of PSA levels is known to precede clinically detectable recurrence by 2 to 5 years, and current clinical practice often relies partially on multiple recent rises in PSA to trigger a change in treatment. However, the longitudinal trajectory for individual markers is often non-linear; in many cases there is a decline immediately following radiation therapy or surgery, a plateau during remission, followed by an exponential rise following the recurrence of the cancer. The aim of this article is to determine the multiple aspects of the longitudinal PSA biomarker trajectory that can be most sensitive for predicting time to clinical recurrence. Joint Bayesian models for the longitudinal measures and event times are utilized based on non-linear hierarchical models, implied by unknown change-points, for the longitudinal trajectories, and a Cox proportional hazard model for progression times, with functionals of the longitudinal parameters as covariates in the Cox model. Using Markov chain Monte Carlo sampling schemes, the joint model is fit to longitudinal PSA measures from 676 patients treated at Massachusetts General Hospital between the years 1988 and 1995 with follow-up to 1999. Based on these data, predictive schemes for detecting cancer recurrence in new patients based on their longitudinal trajectory are derived.

show abstract

Prostate-specific antigen density: A new prognostic indicator for prostate cancer

Cited by 31 publications

References 41 publications

Usefulness of Prostate-Specific Antigen Density as a Diagnostic Test of Prostate Cancer

Usefulness of Prostate-Specific Antigen Density as a Diagnostic Test of Prostate Cancer

Prostate Cancer

Predicting time to prostate cancer recurrence based on joint models for non‐linear longitudinal biomarkers and event time outcomes

Contact Info

Product

Resources

About